REVELATION BIOSCIENCES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REVELATION BIOSCIENCES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.91M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($15.04M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($120.3K) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($10.83M) | Sep 23, 2024 |
| FY2022 | Dec 31, 2021 | ($11.99M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($1.63M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($3.6K) | Jun 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.07M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($7.98M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($8.66M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($10.86M) | Sep 23, 2024 |
| FY2022 | Dec 31, 2021 | ($11.95M) | Mar 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.58M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.62M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $12.21M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $5.50M | Sep 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.04M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $74.16M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $22.7K | Jun 16, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.72M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.91M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.56M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $4.45M | Sep 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.14M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.34M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $26.3K | Jun 16, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.86M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.71M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $6.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.05M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | ($99.5K) | Sep 23, 2024 |
| FY2022 | Dec 31, 2020 | $3.41M | Mar 30, 2023 |
| FY2020 | Dec 31, 2019 | ($3.6K) | Jun 16, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (23) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1,052) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (149) | Sep 23, 2024 |
| FY2022 | Dec 31, 2021 | (42) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (23) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1,052) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (149) | Sep 23, 2024 |
| FY2022 | Dec 31, 2021 | (42) | Mar 30, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.70M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.50M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $11.99M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $5.25M | Sep 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.27M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.7K | Apr 15, 2022 |